MedTrace Logo

Alteration of Temporal Organization of EEG Microstate Sequences During Propofol-induced Loss of Consciousness

NCT02125214 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2015-06-01

No results posted yet for this study

Summary

Temporal dynamics of the EEG microstates show scale-free monofractal properties. This means that information is encoded in the same way at different scales. It may be postulated that these monofractal properties of the EEG microstate sequences constitute a necessary prerequisite of consciousness. We postulate that clinical variations of consciousness may also be linked to alterations of fractal properties of EEG microstates.

Conditions

  • Loss of Consciousness

Interventions

DEVICE

Target Controlled Infusion system (Orchestra Base Primea, Fresenius, France)

Intravenous induction with propofol using the pharmacokinetic model by Schnider et al. The initial cerebral concentration will be 0.5 µg ml-1, which will be increased stepwise by 1.0 µg ml-1 until 2.5 µg ml-1, and then by 0.5 µg ml-1 until loss of consciousness

Sponsors & Collaborators

  • University of Geneva, Switzerland

    collaborator OTHER

  • Ecole Polytechnique Fédérale de Lausanne

    collaborator OTHER

  • Julien Maillard

    lead OTHER

Principal Investigators

  • Martin Tramer, MD, DPhil · University Hospitals of Geneva, Department of Anesthesiology

  • Julien Maillard, MD · University Hospitals of Geneva, Department of Anesthesiology

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2015-04-30
Completion
2015-04-30

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02125214 on ClinicalTrials.gov